Aktienanalyse wird geladen …
GILD · NASDAQ · Biotechnology · USA
149,60 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 29,44 Mrd. | 8,51 Mrd. | 6,78 $ | 1,26 Mrd. | 6 Mio · 0,5 % | 6 Mio · 0,5 % | 78,8 % | 28,9 % | 7,53 $ | 0,71 $ | 3,16 $ |
| 2024 | 28,75 Mrd. | 480 Mio. | 0,38 $ | 1,26 Mrd. | 5,6 Mio · 0,4 % | 8,6 Mio · 0,7 % | 78,3 % | 1,7 % | 8,21 $ | 0,67 $ | 3,08 $ |
| 2023 | 27,12 Mrd. | 5,67 Mrd. | 4,50 $ | 1,26 Mrd. | 5,1 Mio · 0,4 % | 9,1 Mio · 0,7 % | 76 % | 20,9 % | 5,90 $ | 0,61 $ | 3,00 $ |
| 2022 | 27,28 Mrd. | 4,59 Mrd. | 3,64 $ | 1,26 Mrd. | 4,3 Mio · 0,3 % | 4,3 Mio · 0,3 % | 79,3 % | 16,8 % | 6,61 $ | 0,50 $ | 2,92 $ |
| 2021 | 27,31 Mrd. | 6,23 Mrd. | 4,93 $ | 1,26 Mrd. | 4,2 Mio · 0,3 % | 5,2 Mio · 0,4 % | 75,8 % | 22,8 % | 8,56 $ | 0,50 $ | 2,84 $ |
| 2020 | 24,69 Mrd. | 123 Mio. | 0,10 $ | 1,26 Mrd. | 4,3 Mio · 0,3 % | 18,3 Mio · 1,4 % | 81,5 % | 0,5 % | 5,95 $ | 0,51 $ | 2,72 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 7,8 Mrd. | -10,5 Mrd. | -8,44 $ | 1,24 Mrd. | -134,5 % | 2,76 $ |
| Q1 2026 | 6,96 Mrd. | 2,02 Mrd. | 1,61 $ | 1,25 Mrd. | 29 % | 1,94 $ |
| Q4 2025 | 7,93 Mrd. | 2,18 Mrd. | 1,74 $ | 1,25 Mrd. | 27,6 % | 2,49 $ |
| Q3 2025 | 7,77 Mrd. | 3,05 Mrd. | 2,43 $ | 1,25 Mrd. | 39,3 % | 3,16 $ |
| Q2 2025 | 7,08 Mrd. | 1,96 Mrd. | 1,56 $ | 1,26 Mrd. | 27,7 % | 0,57 $ |
| Q1 2025 | 6,67 Mrd. | 1,32 Mrd. | 1,04 $ | 1,26 Mrd. | 19,7 % | 1,31 $ |
| Q4 2024 | 7,57 Mrd. | 1,78 Mrd. | 1,42 $ | — | 23,6 % | 2,25 $ |
| Q3 2024 | 7,55 Mrd. | 1,25 Mrd. | 1,00 $ | 1,25 Mrd. | 16,6 % | 3,32 $ |
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Why Morgan Stanley likes Gilead's HIV prevention play
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs. Gilead Sciences specializes in therapeutic areas including HIV, viral hepatitis, oncology, inflammation, respiratory conditions, and cardiovascular disease. Its current portfolio includes prescription medicines and specialty treatments used in hospitals, clinics, and long-term care settings, supporting patients across global markets. The company also maintains an active pipeline in virology, oncology, and inflammation, reinforcing its role as a major provider of branded therapies in modern healthcare. Headquartered in Foster City, California, Gilead Sciences serves physicians, healthcare systems, and patients through a diversified product portfolio centered on infectious disease and specialty care.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest GILD und jede andere Aktie unbegrenzt.